For Multiple Myeloma Patients, Convenience Now an Important Factor in the Treatment Equation
December 20th 2022The Covid-19 pandemic revealed the advantages of treatment that involved fewer in-person office visits, according to research presented at American Society of Hematology meeting earlier this month. Researchers also saw a notable increase in the use of Darzalex (daratumumab).
Read More
Bispecific Antibody Treatments for Multiple Myeloma Are on Their Way
November 15th 2022Johnson & Johnson’s Tecvayli (teclistamab-cqyv) has been approved by the FDA, and Pfizer’s elranatamab received breakthrough status that should speed its approval. Bispecific antibodies may be a bridge to CAR-T treatments or an alternative to them.
Read More
Adcetris, an Antibody-Drug Conjugate, Shows Promise As a Treatment for Pediatric Hodgkin Lymphoma
November 14th 2022Positive results for Adcetris (brentuximab vedotin) were reported in The New England Journal of Medicine. Further research will include a look at the cost effectiveness of Adcetris.
Read More
Nurse Practitioner-led Care Improved Depression, Anxiety in People with MS
September 5th 2022Research conducted in Canada suggests that people with multiple sclerosis would benefit from being seen by nurse practitioners. However, secondary outcomes in the study did not improve among patients with access to nurse practitioner-led care.
Read More
Neuropsychiatrist Stresses Importance of Depression-MS Link
May 6th 2022Anthony Feinstein, Ph.D., of the University of Toronto, author of a new book about multiple sclerosis and mood, says clinicians and patients need to pay more attention to the effects that depression has on the cognitive abilities of patients with the disease.
Read More
Ultrasound as a Treatment for Liver Cancer Shows Promise
May 2nd 2022An animal study of histotripsy suggests that powerful, focused ultrasound might be a way of treating liver cancer. It is a preliminary study. Much more research will need to be done before the technology is accepted as safe and effective.
Read More
Study Finding: Discontinuation of Natalizumab for Pregnancy Carries Risk of Disability
February 3rd 2022German research team finds that 11% of those who quit the drug for pregnancy had “clinically meaningful disability” one-year postpartum. They don’t advise against quitting the drug but say their findings suggest that patients should be informed of the risk.
Read More
Study of a Tremelimumab-Imfinzi Combination May Lead to New Liver Cancer Treatment Strategy
February 2nd 2022Results of an AstraZeneca trial presented at a recent ASCO meeting sow hopes for a new treatment for patients diagnosed with unresectable hepatocellular carcinoma, the most common type of liver cancer.
Read More
How Bacterial and Viral Infections Affect COPD Inflammation
December 3rd 2021The composition of the microbiota of the airways of people with chronic obstructive pulmonary disorder explains varying degrees of inflammation, according to a review article published recently in the Annals of Medicine.
Read More